Boston Scientific (NYSE:BSX) Reaches New 1-Year Low – Here’s Why

Boston Scientific Corporation (NYSE:BSX) shares reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as $71.83 and last traded at $72.48, with a volume of 2727219 shares trading hands. The stock had previously closed at $73.85.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on BSX. Barclays dropped their price objective on shares of Boston Scientific from $136.00 to $124.00 and set an “overweight” rating for the company in a research note on Tuesday, February 3rd. Truist Financial dropped their price target on shares of Boston Scientific from $120.00 to $95.00 and set a “buy” rating for the company in a research report on Thursday, February 5th. UBS Group decreased their price objective on Boston Scientific from $140.00 to $120.00 and set a “buy” rating on the stock in a report on Thursday, February 5th. The Goldman Sachs Group set a $99.00 target price on Boston Scientific in a report on Thursday, February 5th. Finally, Needham & Company LLC decreased their price target on Boston Scientific from $121.00 to $97.00 and set a “buy” rating on the stock in a research note on Thursday, February 5th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $108.36.

Boston Scientific Stock Performance

The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The company has a market capitalization of $108.22 billion, a P/E ratio of 37.59, a P/E/G ratio of 1.05 and a beta of 0.69. The stock’s 50 day simple moving average is $86.46 and its two-hundred day simple moving average is $95.15.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The firm had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same period last year, the company earned $0.70 earnings per share. The company’s revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, research analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Buying and Selling

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.50% of the company’s stock.

Institutional Investors Weigh In On Boston Scientific

Large investors have recently bought and sold shares of the company. Norges Bank bought a new stake in shares of Boston Scientific in the 4th quarter valued at $2,199,395,000. Edgewood Management LLC bought a new position in Boston Scientific during the second quarter worth about $746,655,000. Parnassus Investments LLC grew its stake in Boston Scientific by 42,978.9% in the third quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock valued at $672,128,000 after acquiring an additional 6,868,459 shares during the period. Egerton Capital UK LLP increased its holdings in shares of Boston Scientific by 223.7% in the third quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock worth $518,660,000 after acquiring an additional 3,671,548 shares in the last quarter. Finally, Maverick Capital Ltd. bought a new stake in shares of Boston Scientific in the fourth quarter worth about $280,735,000. Institutional investors own 89.07% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.